PharmaShots CXO Talks | Women’s History Month Special: A Conversation with Dr. Emanuela Offidani of Tris Pharma

Why It Matters

Better diagnosis and sustained treatment options address a sizable, underserved ADHD market, driving growth for pharma innovators and improving outcomes for patients, especially women.

Key Takeaways

• ADHD underdiagnosed in women due to subtle symptoms
• LiquiXR enables sustained, smoother ADHD drug release
• Tris Pharma expands pipeline with digital therapeutics
• AI and wearables improve ADHD detection and monitoring
• Integrated tech promises personalized, long‑term ADHD management

Pulse Analysis

ADHD is no longer viewed solely as a childhood disorder; recent epidemiological studies estimate that up to 5% of adults worldwide live with the condition. Women, in particular, face diagnostic gaps because their presentations often involve inattentiveness and emotional dysregulation rather than classic hyperactivity. This gender bias has created a sizable unmet need, prompting investors and pharmaceutical firms to prioritize adult‑focused solutions and gender‑sensitive screening tools.

Tris Pharma is leveraging its LiquiXR technology to address adherence challenges that have plagued traditional stimulant formulations. By delivering a controlled, day‑long release, LiquiXR reduces peak‑trough fluctuations, potentially lowering side‑effect profiles and improving daily functioning. The company’s broader pipeline incorporates software‑as‑a‑medical‑device (SaMD) platforms that collect real‑time patient data, enabling clinicians to adjust dosing and behavioral interventions on the fly. Such integrated digital therapeutics position Tris Pharma at the forefront of a market projected to exceed $30 billion by 2030.

Beyond drug delivery, the conversation underscored the transformative role of artificial intelligence and wearable sensors in ADHD care. Machine‑learning algorithms can parse patterns from continuous motion and heart‑rate data, flagging subtle attentional lapses that escape conventional assessments. When combined with clinician‑led interpretation, these tools promise earlier detection, more precise phenotyping, and truly personalized treatment pathways. As regulatory frameworks evolve to accommodate digital diagnostics, companies that master this tech‑clinical nexus are likely to capture significant market share while delivering measurable improvements in patient outcomes.